| ID | Title | Body | Facebook Description | Facebook image | Facebook Title | Facebook Video | Twitter Description | Twitter Image | Twitter Title | Meta tags |
|---|---|---|---|---|---|---|---|---|---|---|
| 445 | Ankit A. Mahadevia, M.D., M.B.A. (February 2017) | Ankit A. Mahadevia is a principal at Atlas Venture, a venture capital firm based in Cambridge, Massachusetts, that finances and builds early-stage enterprises in the life sciences and technology. He focuses on early-stage biopharmaceutical and medical device companies. Mahadevia currently serves on the board of RaNA Therapeutics, Annovation Biopharma, Lumavita AG and Fibrex Medical. He has worked closely on several novel alliances between Atlas Venture and the pharmaceutical/biotechnology industry, including on Atlas’ investment alliances with Shire and Monsanto and on Arteaus, an asset collaboration with Eli Lilly and Company. Mahadevia also serves on the board of the Johns Hopkins Alliance for Technology Transfer and helps organize the annual University Research and Entrepreneurship Symposium in Boston for emerging academic technologies, among other roles promoting translation of biomedical research by biotechnology companies. Mahadevia completed his medical degree at the Johns Hopkins University School of Medicine and received his master’s degree in business administration from the Wharton School at the University of Pennsylvania. | ||||||||
| 444 | Anantha Shekhar, M.D., Ph.D. (2018) | Anantha Shekhar, M.D., Ph.D., is the executive associate dean for research affairs, overseeing all research-related activities, at the Indiana University (IU) School of Medicine and the director of the Indiana Clinical and Translational Sciences Institute (Indiana CTSI). In addition to his IU School of Medicine and Indiana CTSI roles, Shekhar serves as associate vice president for university clinical affairs for IU and executive vice president of academic affairs for clinical research at IU Health. In addition to his role in leading the statewide translational research initiative, Shekhar leads successful basic and clinical research programs in the areas of stress, anxiety and neuropsychiatric disorders. His laboratory has developed some of the best translational models for panic and related anxiety disorders. His work focuses on the role of brain abnormalities that could lead to stress and psychiatric disorders and has more recently extended these studies to the discovery of new treatments. A number of grants from the National Institutes of Health, private foundations and commercial collaborations currently support his research. | ||||||||
| 442 | NCATS Programs & Initiatives | Discover the innovative work of NCATS-supported programs and initiatives. 3-D Tissue Bioprinting Program NCATS experts are applying the techniques of 3-D printing to developing tissue models that mimic the 3-D structure and organization of cells in the tissues of living organisms. A Specialized Platform for Innovative Research Exploration (ASPIRE) By addressing long-standing challenges in the field of chemistry, including lack of standardization, low reproducibility and an inability to predict how new chemicals will behave, ASPIRE is designed to bring novel, safe and effective treatments to more patients more quickly at lower cost. Antiviral Program for Pandemics (APP) The APP is a multi-agency initiative to develop safe and effective oral antivirals for SARS-CoV-2 and other viruses with pandemic potential. As part of the APP, NCATS will apply its expertise and cutting-edge technologies to fill critical needs and work with collaborators to advance drug discovery and development programs for oral antiviral candidates. Assay Development and Screening Technology (ADST) ADST is designed to advance therapeutic development through research and development of innovative assay (test) designs and chemical library screening methods. Assay Guidance Manual The Assay Guidance Manual program provides best-practices resources and training devoted to the successful development of robust, early-stage drug discovery assays. Bespoke Gene Therapy Consortium (BGTC) Part of the Accelerating Medicines Partnership® (AMP®) program, the Bespoke Gene Therapy Consortium (BGTC) is establishing platforms and standards to speed the development and delivery of customized or “bespoke” gene therapies that could treat millions of people affected by rare diseases. Biomedical Data Translator NCATS launched the Biomedical Data Translator (Translator) program to accelerate biomedical translation for the research community. Through this program, NCATS will integrate multiple types of existing data sources and reveal potential relationships across the spectrum of data types. Bridging Interventional Development Gaps (BrIDGs) The BrIDGs program assists researchers in advancing promising therapeutic agents through late-stage preclinical development toward an Investigational New Drug application and clinical testing. Chemistry Technology Chemistry technology experts at NCATS develop small molecules and screening approaches that other scientists can use to pursue innovations in therapeutic development. Clinical and Translational Science Awards (CTSA) Program The CTSA Program addresses the development and implementation of national standards and best practices for translation, from basic discovery to clinical and community-engaged research. Clinical Trial Readiness for Rare Diseases, Disorders and Syndromes (CTR) Grants Program The CTR grants program supports projects focused on collecting the data needed to move promising rare disease therapies and diagnostics to clinical trial. Discovering New Therapeutic Uses for Existing Molecules (New Therapeutic Uses) The New Therapeutic Uses program aims to improve the process of developing new treatments and cures for disease by finding new uses for assets that already have cleared several key steps along the development path (also known as drug repurposing). Early Translation Branch (ETB) ETB researchers advance small molecule therapeutic development through assay (test) design, high-throughput screening and medicinal chemistry. Functional Genomics Lab NCATS’ Functional Genomics Lab is designed to develop and improve RNAi screening approaches to better understand gene function and identify treatment targets. Gene silencing through RNAi has emerged as a powerful tool for understanding gene function. Over the past several years, high-throughput RNAi screens have illuminated a wide variety of biological processes, ranging from genes that affect the activity of therapeutic agents to novel components of signaling pathways. Genetic and Rare Diseases (GARD) Information Center GARD provides up-to-date health information about numerous rare and genetic diseases. The Helping to End Addiction Long-termSM Initiative, or NIH HEAL InitiativeSM NCATS is one of several NIH Institutes and Centers participating in the NIH HEAL Initiative. With Initiative support, NCATS will accelerate the process of developing new treatments for opioid misuse and addiction and for pain. Informatics Research and Scientific Applications Informatics at NCATS plays a key role in organizing, processing, analyzing and interpreting the large quantity and variety of data generated by translational research. Matrix Combination Screening NCATS experts use a technology called matrix combination screening to quickly narrow down a long list of potential drug combinations and find those with the most potential to help patients. Multidisciplinary Machine-Assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey NCATS supports research on innovative approaches to reducing the timeline for accurately diagnosing rare diseases. National COVID Cohort Collaborative (N3C) The N3C is a partnership among the NCATS-supported Clinical and Translational Science Awards (CTSA) Program hubs and the National Center for Data to Health (CD2H), with overall stewardship by NCATS. It aims to create a national resource of COVID-19 clinical data that the research community can use to answer critical research questions as the pandemic continues to evolve. NCATS Toolkit for Patient-Focused Therapy Development The NCATS Toolkit for Patient-Focused Therapy Development is a centralized collection of online resources that can help patient groups advance through the research and development process for new treatments. NIH Common Fund Programs NIH Common Fund programs can provide a strategic and nimble approach to address key roadblocks in biomedical research that impede basic scientific discovery and its translation into improved human health. All NIH Institutes and Centers are involved with the NIH Office of Strategic Coordination in the design, implementation and evaluation of Common Fund programs. OpenData Portal The OpenData Portal is a resource created by NCATS to openly and quickly share COVID-19-related drug repurposing data and experiments for all approved drugs. Pfizer's Centers for Therapeutic Innovation (CTI) The CTI program ran from 2014 to 2019 to help bridge the gap between early scientific discovery and its translation into new medicines through public-private resource sharing. Platform Vector Gene Therapy (PaVe-GT) This NCATS-led pilot project will test whether it is possible to increase the efficiency of gene therapy clinical trial startup by using the same gene delivery system and manufacturing methods for multiple gene therapies. Rare Diseases Clinical Research Network (RDCRN) The RDCRN program is designed to advance medical research on rare diseases by providing support for clinical studies and facilitating collaboration, study enrollment and data sharing. Through the RDCRN consortia, physician scientists and their multidisciplinary teams work together with patient advocacy groups to study more than 200 rare diseases at sites across the nation. Rare Diseases Registry Program (RaDaR) RaDaR, formerly known as the Global Rare Diseases Registry Data Repository program, aims to define best practices for patient registries. RaDaR also strives to identify and adopt standards to support high-quality registries for rare diseases therapeutics development. Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) These programs support NCATS’ mission to transform the translational science process by helping small businesses develop and commercialize new technologies. Stem Cell Translation Laboratory (SCTL) NCATS is working to advance translational methods in stem cell research. Induced pluripotent stem cells are particularly useful because scientists can transform them into many different cell types to use for research or therapies. Therapeutics for Rare and Neglected Diseases (TRND) The TRND program supports preclinical development of therapeutic candidates intended to treat rare or neglected disorders, with the goal of enabling an Investigational New Drug application. Tissue Chip for Drug Screening The Tissue Chip for Drug Screening program aims to develop bioengineered devices to improve the process of predicting whether drugs will be safe or toxic in humans. Toxicology in the 21st Century (Tox21) The Tox21 program is designed to improve toxicity testing methods and enable faster, more efficient evaluation of chemicals’ effects on human health. Translational Approach to COVID-19 NCATS is supporting research activities spanning the translational science spectrum to address the novel coronavirus 2019 (SARS-CoV-2) and the disease it causes (COVID-19). | Discover the innovative work of NCATS-supported programs and initiatives. | /sites/default/files/tox21-chem-tox-robot-carousel.jpg | NCATS Programs & Initiatives | Discover the innovative work of NCATS-supported programs and initiatives. | /sites/default/files/tox21-chem-tox-robot-carousel.jpg | NCATS Programs & Initiatives | ||
| 441 | Invention E-326-2008/0 | Small Molecule Activators of Human Pyruvate Kinase Lead Inventor: Craig Thomas (NCATS) Inventors: Douglas Auld (NCATS), Matthew Boxer (NCATS), James Inglese (NCATS), Jian-kang Jiang (NCATS), Amanda Skoumbourdis (NCATS) Ref. No.: E-326-2008/0 Abstract: NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage over less-specific chemotherapeutics. Publications: Pyruvate Kinase M2 Activators Promote Tetramer Formation and Suppress Tumorigenesis • Nature Chemical Biology • October 2012 • NCATS Chemical Genomics Center Evaluation of Thieno[3,2-b]pyrrole[3,2-d]pyridazinones as Activators of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase • Bioorganic & Medicinal Chemistry Letters • June 2010 • NCATS Chemical Genomics Center Evaluation of Substituted N,N'-diarylsulfonamides as Activators of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase • Journal of Medicinal Chemistry • Feb. 11, 2010 • NCATS Chemical Genomics Center | ||||||||
| 440 | Invention E-308-2009/0 | Caspase 1 Inhibitor Lead Inventor: Craig Thomas (NCATS) Inventor(s): Matthew Boxer (NCATS) Ref. No.: E-308-2009/0 Abstract: Novel and potent caspase 1 inhibitors are available for licensing. In particular, this technology discloses potent and selective caspase 1 inhibitors that target the active site of the enzyme. Publication: A Highly Potent and Selective Caspase 1 Inhibitor that Utilizes a Key 3-Cyanopropanoic Acid Moiety • ChemMedChem • May 3, 2010 • NCATS Chemical Genomics Center | ||||||||
| 439 | Invention E-300-2012/0 | Cotranslational Protein Expression System for High-Throughput Screening Lead Inventor: James Inglese (NCATS) Inventors: Chih-Chien (Ken) Cheng (NCATS), Samuel Hasson (NCATS) Ref. No.: E-300-2012/0 Abstract: Reporter gene-based assays are used extensively in high-throughput screening to identify chemical modulators of cellular pathways for drug discovery and development. However, such screening frequently results in a large number of false “hits” due to interactions of screened compounds with reporter proteins, producing confounding results. Thus, validation of results using these assays often involves significant time and expense. The inventors have developed an assay system that significantly improves detection of target-relevant active compounds by discriminating between signals arising from the target activity and those caused by reporter bias. Publication: A Coincidence Reporter-Gene System for High-Throughput Screening • Nature Methods • October 2012 • NCATS Chemical Genomics Center | ||||||||
| 438 | Invention E-298-2011/1 | Pyruvate Kinase M2 Activators for the Treatment of Cancer Lead Inventor: Craig Thomas (NCATS) Inventors: Douglas S. Auld (NCATS), Matthew Boxer (NCATS), Jian-kang Jiang (NCATS), Min Shen (NCATS) Ref. No.: E-298-2011/1 Abstract: This technology describes a series of small-molecule activators of the pyruvate kinase M2 isoform (PK-M2). Pyruvate kinase (PK) is a critical metabolic enzyme that catalyzes the last step of the glycolytic pathway. It exists in several isoforms with different patterns of tissue expression. One isoform, PK-M2, is expressed in cells with a high rate of nucleic acid synthesis, including most tumors, which makes this enzyme an attractive target for cancer therapy. PK-M2 can occur in either a tetrameric form or a dimeric form in proliferating cells; a high tetramer to dimer ratio leads to energy production, while a low ratio channels metabolites into synthetic processes. In tumor cells, oncoproteins induce dimerization of PK-M2, resulting in the inactive form of the protein and allowing synthesis of building blocks for cell proliferation. Activation of PK-M2 in these cells may prevent the buildup of metabolic intermediates and thereby stall tumor cell proliferation. Further, after embryonic development PK-M2 expression is primarily restricted to tumor cells, so specific activators of PK-M2 would be expected to affect only tumor cells, and would be less likely to be toxic in normal tissues. Publications: Integrated Phosphoproteomic and Metabolomic Profiling Reveals NPM-ALK-Mediated Phosphorylation of PKM2 and Metabolic Reprogramming in Anaplastic Large Cell Lymphoma • Blood • Aug. 8, 2013 • NCATS Chemical Genomics Center Pyruvate Kinase M2 Activators Promote Tetramer Formation and Suppress Tumorigenesis • Nature Chemical Biology • Oct. 2012 • NCATS Chemical Genomics Center Inhibition of Pyruvate Kinase M2 by Reactive Oxygen Species Contributes to Cellular Antioxidant Responses • Science • Dec. 2, 2011 • NCATS Chemical Genomics Center Evaluation of Thieno[3,2-b]pyrrole[3,2-d]pyridazinones as Activators of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase • Bioorganic & Medicinal Chemistry Letters • June 1, 2010 • NCATS Chemical Genomics Center Evaluation of Substituted N,N'-diarylsulfonamides as Activators of the Tumor Cell Specific M2 Isoform of Pyruvate Kinase • Journal of Medicinal Chemistry • Feb. 11, 2010 • NCATS Chemical Genomics Center | ||||||||
| 437 | Invention E-277-2011/0 | Small-Molecule Modulators of Lipid Storage for Treatment of Obesity, Atherosclerosis, Metabolic Syndrome and Lipid Storage Diseases Lead Inventor: Matthew Boxer (NCATS) Ref. No.: E-277-2011/0 Abstract: Lipid droplets are key organelles involved in lipid homeostasis. In normal physiology, these droplets are formed in response to elevated fatty acid levels, and are broken down when needed for energy production. Imbalances in lipid homeostasis trigger compensatory alterations in metabolism that can lead to diseases such as obesity, atherosclerosis, and metabolic syndrome. | ||||||||
| 436 | Invention E-276-2011/0 | Non-toxic Compounds that Inhibit the Formation and Spreading of Tumors Lead Inventor: Samarjit Patnaik (NCATS) Ref. No.: E-276-2011/0 Abstract: Available for licensing are novel pyrrolopyrimidine compounds that disrupt the assembly of the perinucleolar compartment (PNC), a sub-nuclear structure highly prevalent in metastatic tumors. These notable compounds act without overt cytotoxicity. | ||||||||
| 435 | Invention E-268-2009/0 | Delivery of a Therapeutic Protein, Transthyretin (TTR), Across the Blood-Brain Barrier (BBB) as a Treatment for Alzheimer's Disease Lead Inventor: Juan Marugan (NCATS) Inventors: Silvia Muro-Galindo (University of Maryland Biotechnology Institute), Wei Zheng (NCATS) Ref. No.: E-268-2009/0 Abstract: This invention describes products and methods of treating Alzheimer's disease, which is characterized by the formation of amyloid plaques and tangles in areas of the brain critical for learning and memory. |
Last updated on